Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, 70808, USA.
Curr Diab Rep. 2010 Apr;10(2):108-15. doi: 10.1007/s11892-010-0096-4.
Although obesity is a chronic disease like hypertension and diabetes, obesity is not treated with drug combinations as are other chronic diseases. This is because orlistat and sibutramine, the two drugs approved for long-term treatment of obesity, do not result in additive weight loss when combined. This article discusses the history of combination drug therapy for treating obesity, the lessons learned from that experience, and describes the drug combinations now in development. One combination of two standardized dietary herbal supplements that result in clinically significant weight loss is also described. Obesity is poised to enter the era of combination drug therapy, as is now the routine in the treatment of other chronic diseases like hypertension and diabetes. The advent of combination drug therapy for obesity treatment offers hope for increasing the efficacy of obesity pharmacotherapy.
虽然肥胖像高血压和糖尿病一样是一种慢性疾病，但肥胖症的治疗并没有像其他慢性疾病那样采用药物联合治疗。这是因为奥利司他和西布曲明这两种被批准用于长期肥胖治疗的药物联合使用并不会增加体重减轻的效果。本文讨论了联合药物治疗肥胖症的历史，从该经验中吸取的教训，并描述了目前正在开发的药物组合。还描述了一种两种标准化膳食草药补充剂的组合，可导致临床显著的体重减轻。肥胖症即将进入联合药物治疗的时代，就像高血压和糖尿病等其他慢性疾病的常规治疗一样。肥胖症联合药物治疗的出现为增加肥胖症药物治疗的疗效带来了希望。
